Balance and management of CRS and infection following CD19-targeted CAR T-cell therapy in primary refractory high-grade B-cell lymphoma: a case report

BackgroundCD19-targeted chimeric antigen receptor T (CAR T) cell therapy has revolutionized the treatment of refractory/relapsed B-cell malignancies. However, this therapy introduces significant safety concerns, including cytokine release syndrome (CRS) and infections, both of which can lead to life...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Nannan Lu, Yajing Zhang, Chunmeng Wang, Qingming Yang, Guanghua Rong, Yang Liu, Weidong Han
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-07-01
Schriftenreihe:	Frontiers in Hematology
Schlagworte:	B-cell lymphoma CAR T-cell therapy cytokine release syndrome herpesvirus infection corticosteroids
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/frhem.2025.1616504/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!